[go: up one dir, main page]

EP1180025A4 - IL-8 RECEPTOR ANTAGONISTS - Google Patents

IL-8 RECEPTOR ANTAGONISTS

Info

Publication number
EP1180025A4
EP1180025A4 EP00936368A EP00936368A EP1180025A4 EP 1180025 A4 EP1180025 A4 EP 1180025A4 EP 00936368 A EP00936368 A EP 00936368A EP 00936368 A EP00936368 A EP 00936368A EP 1180025 A4 EP1180025 A4 EP 1180025A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00936368A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1180025A1 (en
Inventor
Michael R Palovich
Katherine L Widdowson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1180025A1 publication Critical patent/EP1180025A1/en
Publication of EP1180025A4 publication Critical patent/EP1180025A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/50Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00936368A 1999-05-28 2000-05-26 IL-8 RECEPTOR ANTAGONISTS Withdrawn EP1180025A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13666599P 1999-05-28 1999-05-28
US136665P 1999-05-28
PCT/US2000/014660 WO2000072840A1 (en) 1999-05-28 2000-05-26 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
EP1180025A1 EP1180025A1 (en) 2002-02-20
EP1180025A4 true EP1180025A4 (en) 2002-08-28

Family

ID=22473833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00936368A Withdrawn EP1180025A4 (en) 1999-05-28 2000-05-26 IL-8 RECEPTOR ANTAGONISTS

Country Status (20)

Country Link
EP (1) EP1180025A4 (es)
JP (1) JP2003500443A (es)
KR (1) KR20020016806A (es)
CN (1) CN1352554A (es)
AR (1) AR029361A1 (es)
AU (1) AU766999B2 (es)
BR (1) BR0010863A (es)
CA (1) CA2374295A1 (es)
CO (1) CO5170528A1 (es)
CZ (1) CZ20014246A3 (es)
HK (1) HK1045256A1 (es)
HU (1) HUP0201302A3 (es)
IL (1) IL146053A0 (es)
MX (1) MXPA01012267A (es)
NO (1) NO20015774D0 (es)
NZ (1) NZ514728A (es)
PL (1) PL351947A1 (es)
TR (1) TR200103354T2 (es)
WO (1) WO2000072840A1 (es)
ZA (1) ZA200109627B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6230300A (en) * 1999-07-21 2001-02-13 Kadmus Pharmaceuticals, Inc. Substituted guanidines and the use thereof
EP1413302A3 (en) * 1999-07-21 2004-05-12 Kadmus Pharmaceuticals, Inc. Substituted guanidines for the treatment of pain
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
US6949567B2 (en) 2001-02-26 2005-09-27 4Sc Ag Compounds for the treatment of protozoal diseases
DE10109204A1 (de) * 2001-02-26 2002-09-19 4Sc Ag Verbindungen zur Behandlung von Protozoen-Erkrankungen
JP2006525254A (ja) 2003-05-01 2006-11-09 エフ.ホフマン−ラ ロシュ アーゲー Ipアンタゴニストとしてのイミダゾリン−2−イルアミノ−フェニルアミド類
CN101531621B (zh) * 2009-04-14 2012-08-15 厦门康奥克科技有限公司 一种胍类化合物的制备方法
AU2018354418A1 (en) * 2017-10-27 2020-05-14 Immunebridge Inc. Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006397A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
US5886044A (en) * 1995-02-17 1999-03-23 Smithkline Beecham Corporation IL-8 receptor antagonists
WO2000072800A2 (en) * 1999-05-28 2000-12-07 Smithkline Beecham Corporation Il-8 receptor antagonists
WO2001072960A2 (en) * 2000-03-24 2001-10-04 Smithkline Beecham Corporation Il-8 receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US605977A (en) * 1898-06-21 Bruno richard seifert
US1953494A (en) * 1926-08-26 1934-04-03 Ig Farbenindustrie Ag Process of preparing substituted guanidines
US3914306A (en) * 1972-09-22 1975-10-21 Rorer Inc William H Guanidines
US5696290A (en) * 1994-09-12 1997-12-09 Monsanto Company Synthesis of penta-substituted guanidines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886044A (en) * 1995-02-17 1999-03-23 Smithkline Beecham Corporation IL-8 receptor antagonists
WO1998006397A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
WO2000072800A2 (en) * 1999-05-28 2000-12-07 Smithkline Beecham Corporation Il-8 receptor antagonists
WO2001072960A2 (en) * 2000-03-24 2001-10-04 Smithkline Beecham Corporation Il-8 receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0072840A1 *

Also Published As

Publication number Publication date
HUP0201302A2 (hu) 2002-12-28
IL146053A0 (en) 2002-07-25
HUP0201302A3 (en) 2003-02-28
EP1180025A1 (en) 2002-02-20
NO20015774L (no) 2001-11-27
AU766999B2 (en) 2003-10-30
WO2000072840A1 (en) 2000-12-07
AR029361A1 (es) 2003-06-25
CA2374295A1 (en) 2000-12-07
BR0010863A (pt) 2002-02-19
NZ514728A (en) 2004-04-30
CO5170528A1 (es) 2002-06-27
HK1045256A1 (zh) 2002-11-22
JP2003500443A (ja) 2003-01-07
CZ20014246A3 (cs) 2002-05-15
TR200103354T2 (tr) 2002-06-21
AU5169000A (en) 2000-12-18
CN1352554A (zh) 2002-06-05
ZA200109627B (en) 2002-11-28
MXPA01012267A (es) 2002-07-30
PL351947A1 (en) 2003-07-14
NO20015774D0 (no) 2001-11-27
KR20020016806A (ko) 2002-03-06

Similar Documents

Publication Publication Date Title
EP1284956A4 (en) ANTAGONISTS OF THE IL-8 RECEPTOR
PL352232A1 (en) Il-8 receptor antagonists
DZ3309A1 (en) Il-8 receptor antagonists
AU4560601A (en) Il-8 receptor antagonists
IL145762A0 (en) Il-8 receptor antagonists
PL351946A1 (en) Il-8 receptor antagonists
EP1274415A4 (en) IL-8 RECEPTOR ANTAGONISTS
AP2002002599A0 (en) Il-8 receptor antagonists
EP1265905A4 (en) IL-2 RECEPTOR ANTAGONISTS
IL146053A0 (en) Il-8 receptor antagonists
EP1274413A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP1263427A4 (en) ANTAGONISTS OF THE INTERLEUKIN 8 RECEPTOR
EP1274428A4 (en) INTERLEUKIN-8 (IL-8) RECEPTOR ANTAGONISTS
EP1039903A4 (en) INTERLEUKIN-8 RECEPTOR ANTAGONISTS
EP1047424A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP1194143A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP1261329A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP1185270A4 (en) INTERLEUKIN-8 RECEPTOR ANTOGONISTS
HUP0202004A3 (en) Il-8 receptor antagonists
PL352218A1 (en) Il-8 receptor antagonists
IL140983A0 (en) Il-8 receptor antagonists
EP1265603A4 (en) IL-9 RECEPTOR ANTAGONISTS
EP1237548A4 (en) IL-8 RECEPTOR ANTAGONISTS
ZA985975B (en) IL-8 receptor antagonists
ZA985813B (en) IL-8 receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011031

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20011031

A4 Supplementary search report drawn up and despatched

Effective date: 20020716

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/155 A, 7A 61K 31/4168 B, 7A 61K 31/433 B, 7A 61P 9/10 B, 7A 61P 11/06 B, 7A 61P 13/12 B, 7C 07C 279/18 B, 7C 07D 233/04 B, 7C 07D 233/54 B, 7C 07D 271/10 B, 7C 07D 233/88 B, 7C 07D 233/50 B, 7C 07D 285/08 B

17Q First examination report despatched

Effective date: 20030807

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031218

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1045256

Country of ref document: HK